Allianz SE increased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 283.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,060 shares of the specialty pharmaceutical company’s stock after buying an additional 11,134 shares during the quarter. Allianz SE’s holdings in Jazz Pharmaceuticals were worth $3,487,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its stake in Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares in the last quarter. Quantinno Capital Management LP lifted its position in Jazz Pharmaceuticals by 9.7% during the first quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock worth $36,163,000 after purchasing an additional 16,928 shares during the period. Retirement Systems of Alabama grew its stake in Jazz Pharmaceuticals by 7.6% during the third quarter. Retirement Systems of Alabama now owns 171,801 shares of the specialty pharmaceutical company’s stock worth $39,775,000 after buying an additional 12,138 shares in the last quarter. Tri Locum Partners LP acquired a new stake in Jazz Pharmaceuticals during the first quarter worth about $29,995,000. Finally, Pictet Asset Management Holding SA increased its holdings in Jazz Pharmaceuticals by 1.0% in the 3rd quarter. Pictet Asset Management Holding SA now owns 149,115 shares of the specialty pharmaceutical company’s stock valued at $34,640,000 after buying an additional 1,516 shares during the period. Institutional investors own 89.14% of the company’s stock.
Jazz Pharmaceuticals Trading Down 2.6%
Shares of NASDAQ JAZZ opened at $230.40 on Friday. The firm has a 50 day moving average price of $228.74 and a two-hundred day moving average price of $221.45. The stock has a market cap of $14.79 billion, a P/E ratio of 78.37, a price-to-earnings-growth ratio of 0.42 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 52-week low of $156.95 and a 52-week high of $266.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.64 and a current ratio of 1.82.
Insider Buying and Selling
In other news, EVP Neena Patil sold 1,200 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the transaction, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the transaction, the executive vice president directly owned 65,686 shares in the company, valued at approximately $16,401,794.20. This represents a 53.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 171,342 shares of company stock valued at $41,420,491. Corporate insiders own 4.10% of the company’s stock.
Analyst Ratings Changes
JAZZ has been the topic of several analyst reports. Deutsche Bank increased their price target on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. The Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $337.00 price objective on the stock. Citigroup initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They set a “buy” rating and a $325.00 price objective for the company. Stifel Nicolaus set a $275.00 target price on Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $220.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $294.25.
Check Out Our Latest Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
Further Reading
- Five stocks we like better than Jazz Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
